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Background: Cardiac involvement in sarcoidosis is associated with a poor prognosis. In patients with right sided
heart failure, differentiating between cor-pulmonale, or cardiac sarcoidosis has important implications to
management.
Case presentation: We present the case of a patient with severe but stable pulmonary sarcoidosis and new onset
right sided heart failure despite only mild elevations of pulmonary artery pressure. CMR demonstration of extensive
right ventricular fibrosis with associated dilatation and hypokinesis was a key finding for prognosis and
management of the patient.
Conclusion: Cardiac magnetic resonance (CMR) is the preferred investigation in the diagnosis of cardiac sarcoidosis,
allowing assessment of myocardial inflammation and fibrosis, as well as function, in a manner not matched by
other technologies.
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Sarcoidosis is a multi-organ disease characterised by the
formation of granulomas. The lungs are most commonly
affected. Although cardiac involvement is clinically detected
in only 2% of patients, underdiagnosis is a major issue of
considerable clinical importance. Recent autopsy data sug-
gest that the heart is, in fact, involved in 20-25% of patients
[1], and is directly responsible for up to 25-80% of deaths
attributed to sarcoidosis [2].
In patients with identified cardiac sarcoidosis the left
ventricle (LV) is involved in 98% and the right ventricle
(RV) in up to 40%, usually in the context of biventricular
involvement [3]. Cardiac sarcoidosis affecting predomin-
antly the RV is rare. In a patient with severe, but stable
pulmonary sarcoidosis, we illustrate the important role
of CMR in the diagnosis and management of new onset
RV failure. CMR is able to identify granulomatous infil-
tration of the RV, providing evidence for sarcoidosis as* Correspondence: gfigtree@med.usyd.edu.au
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reproduction in any medium, provided the orthe cause of primary RV failure rather than cor pulmo-
nale as the cause of the patients presentation.
Case presentation
A 42-yr old man initially presented with exertional dys-
pnoea and cough. He had no previous medical history of
significance and was a non-smoker. The clinical examin-
ation and biochemistry were unremarkable, except for
elevated serum angiotensin converting enzyme (ACE).
Chest x-ray showed bulky hilar lymphadenopathy with
extensive reticulonodular and mass like opacities in both
lungs with a middle zone predominance (Figure 1). A
non-contrast computed tomography (CT) scan of the
thorax demonstrated numerous nodules in a perilymphatic
distribution (subpleural and peribronchovascular) together
with perihilar conglomerate masses (Figure 2). Several
enlarged partly calcified hilar, paratracheal and subcarinal
mediastinal lymph nodes were evident. Histopathology of a
transbronchial lung biopsy showed numerous well-formed,
non-necrotising epithelioid granulomas (Figure 3), but
tests for bacilli, fungi and tuberculosis were negative. Based
on clinical, radiological and pathological findings the diag-
nosis of pulmonary sarcoidosis was made.
Five years after initial presentation the patient repre-
sented with dyspnoea and peripheral edema. ACE wasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A frontal chest x-ray showing changes consistent
sarcoidosis. There is bilateral bulky hilar and paratracheal
lymphadenopathy together with extensive, confluent reticulonodular
opacities with a characteristic distribution in the mid and upper zones.
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normal. Findings on chest x-ray and CT scan showed min-
imal change compared to previous imaging. Transthoracic
echocardiography showed normal LV function, and a se-
verely dilated RV with moderately impaired contractile
function. Pulmonary pressures were only mildly elevated
as measured by both echocardiography and right-heart
catheterisation. A cardiac magnetic resonance (CMR) scan
confirmed a dilated RV with impaired systolic function
(Figure 4), RV ejection fraction (EF) was 34% (normalFigure 2 Selected axial (A) and high resolution coronal (B) reformats
and mediastinal adenopathy. Mass-like fibrosis is encasing the hila and c
partially calcified hilar lymph nodes. There are also extensive perivascular a
of the lower zones and right upper lobe bullae.44–63%). Extensive, patchy delayed gadolinium enhance-
ment was observed in the RV free wall, as well as subtle
mid-wall delayed enhancement in the interventricular and
the interatrial septum (Figure 5). The CMR findings led to
a diagnosis of right heart failure secondary to sarcoidosis in-
filtration of the RV wall. The evidence of RV infiltration by
sarcoidosis led to immediate immunosuppressive therapy in
accordance with general recommendations for cardiac
sarcoidosis, and insertion of an implantable cardioverter-
defibrillator (AICD). Follow-up interrogation of the AICD
revealed an episode of non-sustained fast ventricular
tachycardia.Discussion
The diagnosis of cardiac sarcoidosis is often problematic
due to non-specific manifestations, as seen in the present
case. These findings include non-specific EKG changes,
clinical heart failure, abnormal non-specific echocardiog-
raphy findings, elevated serum ACE and sudden death [1].
A multimodality approach has traditionally been used to
determine cardiac involvement [4]. Dyspnoea from LV
heart failure may be attributed to primary pulmonary sar-
coidosis. Signs of right heart failure may be put down to
pulmonary hypertension secondary to pulmonary sarcoid-
osis and cor pulmonale. The diagnosis of cardiac sarcoid-
osis predominantly involving the RV may be even more
problematic and may need to be distinguished from
arrhythmogenic RV cardiomyopathy. Abnormalities on
diagnostic tests such as EKG and echocardiography do
not differentiate cardiac sarcoidosis from other cardiac
diseases. However, in a patient with sarcoidosis any abnor-
mal findings on EKG or echocardiography should lead to
further investigations.from a non-contrast helical CT shows striking bilateral bulky hilar
entral bronchi causing traction bronchiectasis. There are several
nd perilymphatic nodules throughout both lobes with relative sparing
Figure 3 Histology H&E images, original magnifications 200x (A) and 400x (B), of specimen from the transbronchial lung biopsy. It
identified numerous well-formed, non-necrotising epithelioid granulomas (arrows) at both low (A) and intermediate (B) power.
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to identify and characterise cardiac sarcoidosis, with both
positron emission tomography (PET) and CMR shown to
be superior to the previously recommended scintigraphy
[5,6]. CMR has a sensitivity of 100% and a specificity of
78% for the diagnosis of cardiac sarcoidosis [6]. CMR
allows for accurate assessment of cardiac function and
comprehensive tissue characterisation. Functional CMR
images assess ventricular volumes, function and focal
wall motion abnormalities; T2 weighted black blood
images can be used to identify oedema and the presence
of active inflammation; and delayed gadolinium enhance-
ment images detect scarring with great accuracy [7]. NewFigure 4 Functional (cine) cardiac magnetic resonance images in the
The images show poor contraction of the right ventricle (RV) free wall (arroemerging pre- and postcontrast T1 mapping CMR tech-
niques may provide information regarding interstitial
fibrosis and extracellular matrix volume [8]. However,
these new techniques are not yet performed routinely in
clinical practice. The pattern of oedema or myocardial late
enhancement is used to differentiate between non-
ischemic and ischemic scarring. Typical cardiac sarcoid-
osis lesions seen with CMR are focal mid-myocardial or
sub-epicardial scarring, whereas sub-endocardial lesions,
typical for coronary artery related infarction, is rare with
sarcoidosis [6]. CMR is the optimal method of imaging the
RV, both in regards to its contractile function, as well as
the presence of sarcoid infiltration with late enhancement,four-chamber image plane in diastole (A) and systole (B).
ws in A and B), but normal contraction of the left ventricle (LV).
Figure 5 Delayed enhancement cardiac magnetic resonance images in the four-chamber (A) and short axis (B) image plane. The images
show a patchy pattern of delayed enhancement (arrows) in the subepicardial and mid-wall of the right ventricle free wall, interventricular and
interatrial septum. The myocardium of the left ventricle free wall is normal.
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the evaluation of anti-inflammatory treatment [6]. The
high sensitivity of 18F-FDG PET for active inflammatory
lesions is partially countered by the reduced specificity of
18F-FDG in the heart due to the high metabolic rate of
the myocardium. However, it is very likely that a comple-
mentary role for PET and CMR in the Clinic will be
defined in the near future.
Limitations of CMR include significant claustrophobia
in up to 5% of patients and contraindication to gadolinium
administration in patients with impaired renal function,
and inability to image patients with non-MRI compatible
pacemakers or AICDs. Furthermore, although CMR is su-
perior to echocardiography in imaging RV structure and
function, the thin walled nature of the RV makes delayed
enhancement difficult to discriminate from artefact. This
is even more problematic when using T2 based imaging
sequences to identify oedema in the RV.
Although patients with cardiac sarcoidosis are at risk of
adverse cardiac events including ventricular tachycardia
(VT) and CMR is predictive of this [9], the role of prophy-
lactic AICD is not well defined. It is clear that all patients
with established VT should receive an AICD and anti-
arrhythmic therapy. The patient presented received an
AICD due to the extensive nature of RV involvement, with
associated dilatation and impaired systolic function. The
recorded episode of rapid ventricular tachycardia suggests
that this was an appropriate management decision.
Conclusion
CMR is critical in differentiating the cause of new onset
right heart failure in a patient with stable pulmonary sar-
coidosis, but no significant pulmonary hypertension. Major
cardiac events, including sudden cardiac death often occur
in patients despite normal EKG and echocardiography.
The excellent sensitivity of CMR, its ability to predictcardiac events, and its lack of ionizing radiation has led to
the proposal by many experts that CMR should be part of
the routine work-up in any patient with sarcoidosis.Consent
Written informed consent was obtained from the patient
for publication of this case and any accompanying images.
A copy of the written consent is avaliable for review by the
Series Editor of this journal.
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